Jose Henao Correa, MD
Pulmonary Disease · Tupelo, MSNPI 1487109260
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 227 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,214, more than ten times the $29 reported in 2020. That places this record below the midpoint for pulmonary disease clinicians in MS, where the typical reported total is $4,861.
Across 227 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$823
- GSK$769
- Boehringer Ingelheim$490
- Merck$367
- Regeneron Healthcare Solutions, Inc.$316
- Harmony Biosciences LLC$275
- plus $1K from 24 others
What the payments were for
- Food & beverage$4,39899%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $823 |
| GSK | 53 | $769 |
| Boehringer Ingelheim | 27 | $490 |
| Merck | 20 | $367 |
| Regeneron Healthcare Solutions, Inc. | 14 | $316 |
| Harmony Biosciences LLC | 11 | $275 |
| Sanofi | 10 | $230 |
| Mallinckrodt Hospital Products Inc. | 6 | $198 |
| Insmed, Inc. | 7 | $133 |
| Jazz Pharmaceuticals Inc. | 4 | $86 |
| Novartis | 5 | $86 |
| Amgen | 4 | $66 |
| Grifols USA, LLC | 3 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $60 |
| Mylan Specialty L.p. | 3 | $54 |
| United Therapeutics Corporation | 3 | $53 |
| Pulmonx Corporation | 2 | $47 |
| Baxter Healthcare | 3 | $42 |
| Fisher & Paykel Healthcare Inc | 2 | $39 |
| Abiomed | 2 | $30 |
| Mayne Pharma Commercial LLC | 1 | $29 |
| La Jolla Pharmaceutical Company | 2 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Verona Pharma, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| Viatris Specialty LLC | 1 | $19 |
| AbbVie | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Bayer | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,426 in reported general payments places this provider in the 45th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 34 | $431,758 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 377 | $253,094 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 166 | $77,151 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 48 | $31,272 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $14,178 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $12,253 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 414 | $10,972 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $9,245 |
| Spiriva HandihalerTiotropium Bromide | 17 | $8,335 |
| Ventolin HfaAlbuterol Sulfate | 102 | $6,437 |
| BreynaBudesonide/Formoterol Fumarate | 20 | $4,654 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $3,708 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $3,465 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $2,961 |
| Varenicline Tartrate | 14 | $1,609 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat | $490 | $445,93660 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $769 | $351,743597 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $823 | $34,98065 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Tupelo
- Jaime UngoTupelo$29K
- William EdmonsonTupelo$15K
- Paul PerryTupelo$13K
- Kevin HarbourTupelo$13K
- Robert StewartTupelo$10K
- David WittyTupelo$7K
- Ryan SessumsTupelo$4K
- William FrazierCanton$809K
- Demondes HaynesJackson$809K
- Bobby TullosGulfport$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.